Fda Ema
Fda Ema - Related Videos
10:29
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
0 Views •
Cited by 83 •
2010
In this article, we examine the methodology and considerations relevant to the FDA approved depression treatment protocol using the Neuronetics NeuroStar TMS device.
10:03
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
0 Views •
Cited by 24 •
2013
Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe vaccines to combat human...
05:05
Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
0 Views •
Cited by 95 •
2011
We describe a technique for labeling and tracking stem cells with FDA-approved, superparamagnetic iron oxide (SPIO), ferumoxytol (Feraheme). This cellular imaging technique that utilizes magnetic resonance (MR) imaging for visualization, is readily accessible for long-term monitoring and diagnosis of successful or unsuccessful stem cell engraftments in patients.
01:26
FDA Approved Drugs: Changes to Approved Drugs
0 Views •
2025
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
10:38
In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
0 Views •
Cited by 17 •
2016
The alkaline comet assay measures DNA strand breaks in eukaryotic cells. By adding an Endonuclease III or human 8-oxoguanine-DNA-N-glycosylase digestion step, the assay can efficiently detect oxidative DNA damage. We describe methods for using these assays to detect DNA damage in rat liver.
FAQs
The benefit-risk profile helps regulators judge whether a medicine’s demonstrated benefits justify its identified risks for the intended use. This assessment integrates findings from preclinical work, clinical trials, product quality, and manufacturing controls rather than relying on a single result. The conclusion influences marketing authorization and provides a framework for interpreting later safety information.
Clinical efficacy alone does not establish that a product can be consistently supplied or used safely. FDA and EMA reviews also examine product quality and manufacturing processes, linking laboratory and production controls to the reliability of the medicine evaluated in trials. This broader assessment supports consistent clinical standards and strengthens confidence in the evidence submitted for authorization.
FDA and EMA operate within different regulatory settings, associated with the United States and European Union, respectively. Their review decisions and guidance can therefore shape development and evidence interpretation across jurisdictions in distinct ways. Understanding both perspectives helps research teams plan international studies, recognize submission expectations, and compare regulatory conclusions without assuming that one agency’s process automatically represents the other’s.
Regulatory guidance influences how researchers plan clinical trials and organize the evidence needed for later review. It can shape the development strategy, the way clinical questions are addressed, and how results are prepared for submission. Considering FDA and EMA expectations early helps teams align study planning with eventual evaluations of safety, efficacy, quality, and benefit-risk.
A development pathway generally connects preclinical studies with clinical trials, regulatory review, marketing authorization, and subsequent safety monitoring. Researchers should consider how evidence accumulates across these stages rather than treating submission as an isolated event. This framework helps teams organize information on efficacy, safety, quality, and manufacturing so agencies can evaluate the product’s overall benefit-risk profile.
Pharmacovigilance provides ongoing safety oversight after marketing authorization. Continued monitoring allows regulators and clinical stakeholders to evaluate safety information as broader use generates additional evidence beyond the original development program. This post-authorization perspective complements preclinical and clinical findings, supports continued assessment of benefit-risk, and helps inform how medicines are understood and used in clinical settings.